A real-world retrospective, observational study of first-line pembrolizumab plus chemotherapy for metastatic non-squamous non-small cell lung cancer with PD-L1 tumor proportion score < 50% (PEMBROREAL)
ConclusionThe results of the PEMBROREAL study have shown that the combined treatment of pembrolizumab with pemetrexed and platinum is effective for metastatic non-squamous NSCLC, even for patients with PD-L1 levels below 50%, despite the differences in patient demographics and pathological features compared to the Keynote-189 study. The adverse events reported during the study were more typical of chemotherapy treatment rather than immunotherapy, and physicians were able to manage them easily.
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Alimta | Cancer | Cancer & Oncology | Chemotherapy | Immunotherapy | Italy Health | Lung Cancer | Non-Small Cell Lung Cancer | Study | Toxicology | UK Health